Vaxart Provides Business Update; Expects Net Proceeds From $40M Offering And Reimbursment Under Project NextGen Award Of Up To $453M To Extend Cash Runaway Into 2026

Benzinga · Jun 18 04:08

— Cash runway extended into 2026 —

— Received one of the largest BARDA-funded Project NextGen Awards to date, up to $453 million —

— Company well-capitalized to execute on multiple key clinical and regulatory milestones in COVID-19 and norovirus programs —

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

Vaxart Provides Business Update; Expects Net Proceeds From $40M Offering And Reimbursment Under Project NextGen Award Of Up To $453M To Extend Cash Runaway Into 2026

Risk Disclaimer